4-(苄氧基)-2-羟基苯甲酸甲酯 | 5427-29-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(苄氧基)-2-羟基苯甲酸甲酯
• 英文名称: methyl 2-hydroxy-4-benzyloxybenzoate
• 英文别名: methyl 4-(benzyloxy)-2-hydroxybenzoate；4-benzyloxy-2-hydroxybenzoic acid methyl ester；methyl 2-hydroxy-4-phenylmethoxybenzoate
• CAS: 5427-29-2
• 化学式: C₁₅H₁₄O₄
• mdl: MFCD01098916
• 分子量: 258.274
• InChiKey: PHYPTZODBQEMJU-UHFFFAOYSA-N

物化性质

• 熔点：
  102-104 °C
• 沸点：
  404.8±30.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿；丙酮

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-(苄氧基)-2-羟基苯甲酸甲酯 在 potassium tert-butylate 、 溴 、 sodium 、 copper dichloride 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 Methyl 5-methoxy-2-(methoxymethoxy)-4-phenylmethoxybenzoate
  参考文献：
  名称：

  Total Syntheses of Lamellarin D and H. The First Synthesis of Lamellarin-Class Marine Alkaloids

  摘要：

  Total syntheses of marine polyaromatic alkaloids, lamellarin D (1) and H (2), are described. The pentacyclic lamellarin ring system was constructed by B-ylide mediated pyrrole ring formation and subsequent lactonization of 4 obtained by an assembly of known benzylisoquinoline 5, benzoate 6 and ethyl bromoacetate. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(97)00287-1
• 作为产物：
  描述：

  methyl 2,4-bis(benzyloxy)benzoate 在 甲醇 、 silica-immobilized p-TsOH 作用下， 以 甲苯 为溶剂， 反应 4.5h， 以98%的产率得到4-(苄氧基)-2-羟基苯甲酸甲酯
  参考文献：
  名称：

  Factors affecting orthogonality in the deprotection of 2,4-di-protected aromatic ethers employing solid-supported acids

  摘要：

  Selective deprotection of aromatic ethers bearing two protecting groups on the same aromatic ring by solid-supported acids (Amberlyst-15 and PTS-Si) was systematically investigated. ortho-Directing protonation by the carbonyl group as well as carbocation stability and quenching are the important determining factors for the orthogonal deprotection process. Stablilized carbocations (e.g., those from the MOM and PMB groups) could be removed with high selectivity. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2009.03.089

文献信息

• [EN] 1 -HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS<br/>[FR] 1-HYDROXY-BENZOOXABOROLES COMME AGENTS ANTIPARASITAIRES
  申请人：LILLY CO ELI

  公开号：WO2014149793A1

  公开（公告）日：2014-09-25

  Provided are compounds useful for controlling endoparasites both in animals and agriculture. Further provided are methods for controlling endoparasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling endoparasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. The claimed compounds are described by the following Markush formula:A typical example for a compound according to above formula is: A typical example for a compound according to above formula is:

  提供了一些在动物和农业中控制内寄生虫的化合物。此外，还提供了一种通过向动物施用上述化合物或其药学上可接受的盐的有效量来控制动物内寄生虫侵染的方法，以及使用上述化合物或其可接受的盐以及可接受的载体来控制内寄生虫侵染的配方。所述的化合物由以下Markush公式描述：根据上述公式的化合物的典型示例是：
• Aromatically substituted .omega.-amino-alkanoic acid amides and alkanoic
  申请人：Ciba-Geigy Corporation

  公开号：US05641778A1

  公开（公告）日：1997-06-24

  Compounds of formula I ##STR1## wherein R.sub.1 is a 2-R.sub.A -3-R.sub.B -phenyl radical, a 2-R.sub.A -4-R.sub.C -phenyl radical, a 2-R.sub.A -pyridin-3-yl radical, a 3-R.sub.A -pyridin-2-yl radical or a 1-R.sub.D -indol-3-yl radical, wherein one of the radicals R.sub.A and R.sub.B is an aliphatic or heterocycloaliphatic-aliphatic radical or free or aliphatically, araliphatically or heteroaraliphatically etherified hydroxy and the other is hydrogen, an aliphatic radical or free or esterified or amidated carboxy, R.sub.C is hydrogen, an aliphatic radical, free or aliphatically, araliphatically, heteroaraliphatically or heteroarylaliphatically etherified hydroxy or an unsubstituted or heteroaliphatically substituted amino group, and R.sub.D is an aliphatic, araliphatic or heteroaliphatic radical, one of the radicals X.sub.1 and X.sub.2 is carbonyl and the other is methylene, R.sub.2 is an aliphatic radical, R.sub.3 is unsubstituted or aliphatically substituted amino, R.sub.4 is an aliphatic or araliphatic radical, and R.sub.5 is an aliphatic or cycloaliphatic-aliphatic radical or an optionally hydrogenated and/or oxo-substituted heteroaryl radical or an optionally hydrogenated and/or oxo-substituted heteroaryl or heteroaliphatyl radical bonded via a carbon atom, and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive active ingredients of medicaments.

  式I的化合物##STR1##其中R.sub.1是2-R.sub.A-3-R.sub.B-苯基基团，2-R.sub.A-4-R.sub.C-苯基基团，2-R.sub.A-吡啶-3-基基团，3-R.sub.A-吡啶-2-基基团或1-R.sub.D-吲哚-3-基基团，其中基团R.sub.A和R.sub.B中的一个是脂肪或杂环脂肪-脂肪基团或自由或脂肪基、芳基脂肪基或杂芳基脂肪基醚化的羟基，另一个是氢、脂肪基或自由或酯化或酰胺化的羧基，R.sub.C是氢、脂肪基、自由或脂肪基、芳基脂肪基、杂芳基脂肪基或未取代或杂脂肪基取代的氨基团，R.sub.D是脂肪、芳基或杂脂肪基，基团X.sub.1和X.sub.2中的一个是羰基，另一个是亚甲基，R.sub.2是脂肪基，R.sub.3是未取代或脂肪取代的氨基，R.sub.4是脂肪或芳基基团，R.sub.5是脂肪或环脂肪-脂肪基团或可选择氢化和/或氧代取代的杂芳基基团或通过碳原子键合的可选择氢化和/或氧代取代的杂芳基或杂脂肪基基团，以及其盐，具有抑制肾素的性质，并可用作药物的降压活性成分。
• [EN] METHODS OF TREATING ALZHEIMER'S DISEASE USING AROMATICALLY SUBSTITUTED omega-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES<br/>[FR] METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER AU MOYEN D'AMIDES D'ACIDE O-AMINO-ALCANOIQUE A SUBSTITUTIONS AROMATIQUES ET DE DIAMIDES D'ACIDE ALCANOIQUE
  申请人：ELAN PHARM INC

  公开号：WO2003103652A1

  公开（公告）日：2003-12-18

  Disclosed.are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables R1, R2, R3, R4, R5, X1, and X2 are defined herein.

  披露了治疗阿尔茨海默病和其他疾病，和/或抑制β-分泌酶酶，和/或通过使用式(I)化合物在哺乳动物体内抑制Aβ肽沉积的方法，其中变量R1、R2、R3、R4、R5、X1和X2在此处定义。
• [EN] RORGAMMAT INHIBITORS<br/>[FR] INHIBITEURS DE RORGAMMAT
  申请人：MERCK SHARP & DOHME

  公开号：WO2012106995A1

  公开（公告）日：2012-08-16

  The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.

  本发明涉及按照式(I)的化合物或其药用可接受的盐或溶剂。这些化合物可用于治疗RORgammaT介导的疾病或症状。
• Spirocyclopropane compounds. IV. Synthesis of 5-acetylspiro(benzofuran-2(3H),1'-cyclopropan)-3-one related compounds for evaluation as gastric antisecretory and antiulcer agents.
  作者：MASAZUMI WATANABE、MITSURU KAWADA、TAKEO HIRATA、YOSHITAKA MAKI、ISUKE IMADA

  DOI：10.1248/cpb.32.3551

  日期：——

  5-Acetylspiro [benzofuran-2 (3H), 1'-cyclopropan]-3-one (1a) shows potent gastric antisecretory and antiulcer activities in rats. In an attempt to improve the pharmacological profile of 1a, we synthesized positional isomers, as well as the prenyloxy and oxime derivatives. Evaluation of their antisecretory activities and protective activities against gastric lesions induced by water-immersion restraint stress in the rat indicated that the 7-acetyl derivative (1d) was equipotent to 1a.

  5-乙酰基螺[苯并呋喃-2(3H)，1'-环丙烷]-3-酮（1a）在大鼠中显示出强大的胃抗分泌和抗溃疡活性。为了改善1a的药理学特性，我们合成了位置异构体以及 prenyl 氧基和肟衍生物。评估它们抗分泌活性以及对大鼠水浸束缚应激诱导的胃损伤的保护作用表明，7-乙酰衍生物（1d）与1a等效。